title: Critical illness-related corticosteroid insufficiency in cancer patients.
abstract: OBJECTIVE
  Critically ill cancer patients with sepsis represent a high-risk sub-group for the development of critical illness-related corticosteroid insufficiency (CIRCI); however, the incidence of CIRCI in this population is unknown. The purpose of this study was to determine the incidence of CIRCI in cancer patients with severe sepsis or septic shock.
  
  
  METHODS
  A single-center, retrospective, observational study was conducted in a 52-bed medical-surgical intensive care unit of a National Cancer Institute-recognized academic oncology institution. Eighty-six consecutive patients with a diagnosis of severe sepsis or septic shock who received a high-dose 250-μg cosyntropin stimulation test were included. CIRCI was identified by a maximum delta serum cortisol of 9 μg/dL or less post cosyntropin.
  
  
  RESULTS
  Overall, 59% (95% CI, 48-70%) of cancer patients with severe sepsis or septic shock were determined to have CIRCI. When compared to patients without CIRCI, patients with CIRCI had higher baseline serum cortisol (median, 26.3 versus 14.7 μg/dL; p = 0.002) and lower delta cortisol levels (median, 3.1 versus 12.5 μg/dL; p < 0.001). Mortality did not differ between the two groups. An inverse relationship was identified between baseline serum cortisol and maximum delta cortisol (maximum delta cortisol = -0.27 × baseline cortisol + 14.30; R (2) = 0.208, p < 0.001).
  
  
  CONCLUSIONS
  The incidence of CIRCI in cancer patients with severe sepsis or septic shock appears high. Further large-scale prospective trials are needed to confirm these findings.
authors: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 377, Houston, TX 77030-4009, USA. jjbruno@mdanderson.org
authors: Jeffrey Joseph
authors: JJ
authors: Bruno
authors: Mike
authors: M
authors: Hernandez
authors: Shubhra
authors: S
authors: Ghosh
authors: S Egbert
authors: SE
authors: Pravinkumar
references: Crit Care Med. 2008 Jun;36(6):1937-49
references: 18496365
references: N Engl J Med. 2004 Apr 15;350(16):1629-38
references: 15084695
references: Br J Clin Pharmacol. 1998 Dec;46(6):589-97
references: 9862249
references: N Engl J Med. 2003 Feb 20;348(8):727-34
references: 12594318
references: Intensive Care Med. 2006 Aug;32(8):1184-90
references: 16786331
references: J Crit Care. 2012 Aug;27(4):351-61
references: 22341726
references: Cancer. 1999 Sep 15;86(6):1044-9
references: 10491532
references: Eur J Cancer. 2002 Jul;38(11):1490-4
references: 12110495
references: Shock. 2003 Jan;19(1):13-5
references: 12558137
references: JAMA. 2002 Aug 21;288(7):862-71
references: 12186604
references: J Crit Care. 2006 Mar;21(1):73-7
references: 16616627
references: N Engl J Med. 2008 Jan 10;358(2):111-24
references: 18184957
references: J Clin Endocrinol Metab. 2003 Jul;88(7):3149-54
references: 12843158
references: Crit Care Med. 2005 Nov;33(11):2457-64
references: 16276166
references: JAMA. 2000 Feb 23;283(8):1038-45
references: 10697064
references: Am J Respir Crit Care Med. 2006 Dec 15;174(12):1319-26
references: 16973979
references: Intensive Care Med. 1994 Aug;20(7):489-95
references: 7995865
references: Lancet. 1991 Mar 9;337(8741):582-3
references: 1671944
references: Intensive Care Med. 1996 Sep;22(9):894-9
references: 8905423
references: Intensive Care Med. 1995 Jan;21(1):57-62
references: 7560475
references: Crit Care Med. 2008 Jan;36(1):296-327
references: 18158437
references: Crit Care Med. 2003 Jan;31(1):141-5
references: 12545007
references: Crit Care Med. 2005 Nov;33(11):2479-86
references: 16276169
references: Crit Care. 2002 Jun;6(3):251-9
references: 12133187
references: J Clin Endocrinol Metab. 1985 Mar;60(3):585-9
references: 2982902
references: Intern Med. 2002 Jun;41(6):453-7
references: 12135178
references: Crit Care Med. 2003 Jun;31(6):1668-75
references: 12794402